Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations

Back

ESC Professional Premium Access

Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations

Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

Topic: Lipid-Lowering Agents

Speaker: Miss D. Dunca (London, GB)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Miss Diana Dunca

University College London, London (United Kingdom of Great Britain & Northern Ireland)

0 follower

5 more presentations in this session

Cross-sectional analysis of demographic and clinical characteristics of patients using icosapent ethyl

Speaker: Doctor J. Nelson (Fresno, US)

Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study

Speaker: Professor S. Yamashita (Izumisano, JP)

RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys

Speaker: Professor L. Gan (Goteborg, SE)

Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation

Speaker: Doctor L. Michael (Indianapolis, US)

Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome

Speaker: Doctor A. Nakamura (Morioka, JP)

Access the full session

Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

Speakers: Miss D. Dunca, Doctor J. Nelson, Professor S. Yamashita, Professor L. Gan, Doctor L. Michael...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations

About the speaker

Miss Diana Dunca

5 more presentations in this session

Cross-sectional analysis of demographic and clinical characteristics of patients using icosapent ethyl

Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study

RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys

Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation

Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome

Access the full session

Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

About the event

ESC Congress 2023

ESC 365 is supported by